Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Express Scripts
Baxter
McKinsey
UBS
Teva
Colorcon
Daiichi Sankyo
Mallinckrodt
Cerilliant

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,741,268

« Back to Dashboard

Summary for Patent: 7,741,268
Title:Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
Abstract:The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic.RTM. F77, Pluronic F87, Pluronic F88 and Pluronic F68.
Inventor(s): Samaritani; Fabrizio (Rome, IT), Donati; Piergiorgio (Morges, CH)
Assignee: Ares Trading S.A. (Aubonne, CH)
Application Number:10/551,840
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 7,741,268

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Emd Serono GONAL-F RFF REDI-JECT follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021684-001 May 25, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Emd Serono GONAL-F RFF REDI-JECT follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021684-002 May 25, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Emd Serono GONAL-F RFF REDI-JECT follitropin alfa/beta INJECTABLE;SUBCUTANEOUS 021684-003 May 25, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,741,268

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03100882Apr 02, 2003
03101543May 27, 2003
03101828Jun 20, 2003
PCT Information
PCT FiledApril 02, 2004PCT Application Number:PCT/EP2004/050432
PCT Publication Date:October 14, 2004PCT Publication Number: WO2004/087213

International Patents Family Members for US Patent 7,741,268

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1610822 ➤ Subscribe
New Zealand 542247 ➤ Subscribe
Norway 330214 ➤ Subscribe
Norway 20054982 ➤ Subscribe
Malaysia 144814 ➤ Subscribe
Mexico PA05010635 ➤ Subscribe
Montenegro P31708 ➤ Subscribe
South Korea 101105486 ➤ Subscribe
South Korea 20050110037 ➤ Subscribe
Japan 4699991 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Covington
Novartis
UBS
Fish and Richardson
Daiichi Sankyo
QuintilesIMS
US Department of Justice
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot